---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000064"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-04-08T23:59:59+00:00"
generated_at: "2026-05-23T18:58:39.572401+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cartesian reports Descartes-08 Phase 2b MG data: sustained 12-month benefit, Phase 3 on track

## Summary
- Average MG-ADL reduction of 4.8 points at Month 12; 83% maintained clinically meaningful response.
- In biologic-naive subgroup (n=7): avg 7.1-point MG-ADL reduction, 57% achieved minimum symptom expression (MG-ADL 0-1) at Month 12.
- No new safety signals; no CRS or ICANS; supports outpatient administration without lymphodepleting chemo.
- Phase 3 AURORA trial on track to dose first patient in Q2 2025; FDA SPA agreement for trial design.

## SEC filing metadata
- accession: 0001453687-25-000064
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000064/0001453687-25-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000064/rnac-20250408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000064
- JSON: https://secwatch.observer/filing/0001453687-25-000064.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.